Kardium
Kardium Inc. is a medical device company revolutionizing atrial fibrillation management with its Globe® Pulsed Field System — a single-spherical, 122-electrode catheter that seamlessly integrates rapid pulmonary vein isolation, continuous high-definition 3D mapping, and precise atrial ablation. In the global PULSAR IDE trial involving 183 patients across North America and Europe, the system achieved 100 % acute procedural success, 78% freedom from atrial arrhythmia at 12 months, zero device-related primary safety events, an average of just 1.2 applications per vein, and mean vein isolation in 25 minutes. With a planned commercial launch in late 2025, the Globe is poised to deliver potentially safer, faster, all-in-one workflow solutions that stand to significantly improve procedural efficiency and long-term outcomes for millions living with atrial fibrillation worldwide.
Learn more at